Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary
- PMID: 18974749
- DOI: 10.1038/nrd2358
Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary
Abstract
Therapeutic strategies for multiple sclerosis have radically changed in the past 15 years. Five regulatory-approved immunomodulatory agents are reasonably effective in the treatment of relapsing-remitting multiple sclerosis, and appear to delay the time to progression to disabling stages. Inhibiting disease progression remains the central challenge for the development of improved therapies. As understanding of the immunopathogenesis of multiple sclerosis has advanced, a number of novel potential therapeutics have been identified, and are discussed here. It has also become apparent that traditional views of multiple sclerosis simply as a CD4+ T-cell-mediated disease of the central nervous system are incomplete. The pathogenic role of other immune components such as the innate immune system, regulatory T cells, T helper 17 cells and B cells is reaching centre stage, opening up exciting avenues and novel potential targets to affect the natural course of multiple sclerosis.
Comment in
-
Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin.Nat Rev Drug Discov. 2009 Jul;8(7):594. doi: 10.1038/nrd2358-c1. Nat Rev Drug Discov. 2009. PMID: 19568285 No abstract available.
Similar articles
-
Glatiramer in the treatment of multiple sclerosis.Int J Nanomedicine. 2006;1(3):283-9. Int J Nanomedicine. 2006. PMID: 17717969 Free PMC article. Review.
-
Evolving therapies for multiple sclerosis.Int Rev Neurobiol. 2007;79:571-88. doi: 10.1016/S0074-7742(07)79025-6. Int Rev Neurobiol. 2007. PMID: 17531859 Review.
-
Immunopathogenesis of multiple sclerosis.Int Rev Neurobiol. 2007;79:99-126. doi: 10.1016/S0074-7742(07)79005-0. Int Rev Neurobiol. 2007. PMID: 17531839 Review.
-
Toward the development of rational therapies in multiple sclerosis: what is on the horizon?Ann Neurol. 2007 Oct;62(4):314-26. doi: 10.1002/ana.21289. Ann Neurol. 2007. PMID: 17969020 Review.
-
Emerging therapies in multiple sclerosis.Expert Opin Emerg Drugs. 2005 Nov;10(4):797-816. doi: 10.1517/14728214.10.4.797. Expert Opin Emerg Drugs. 2005. PMID: 16262563 Review.
Cited by
-
Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. doi: 10.1038/nri3834. Nat Rev Immunol. 2015. PMID: 26008591 Review.
-
A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activation.Arthritis Res Ther. 2012 Jan 17;14(1):R9. doi: 10.1186/ar3683. Arthritis Res Ther. 2012. PMID: 22251404 Free PMC article.
-
Targeting Phosphodiesterases-Towards a Tailor-Made Approach in Multiple Sclerosis Treatment.Front Immunol. 2019 Jul 24;10:1727. doi: 10.3389/fimmu.2019.01727. eCollection 2019. Front Immunol. 2019. PMID: 31396231 Free PMC article. Review.
-
Inflammation induced neurological handicap processes in multiple sclerosis: new insights from preclinical studies.J Neural Transm (Vienna). 2010 Aug;117(8):907-17. doi: 10.1007/s00702-010-0432-5. Epub 2010 Jun 23. J Neural Transm (Vienna). 2010. PMID: 20571836 Review.
-
Trial watch: Phase III promise for oral multiple sclerosis therapy.Nat Rev Drug Discov. 2009 Feb;8(2):98. doi: 10.1038/nrd2821. Nat Rev Drug Discov. 2009. PMID: 19180099 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
